Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report issued on Wednesday, Benzinga reports. The brokerage currently has a $92.00 target price on the stock. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ FY2025 earnings at $0.24 EPS, FY2026 earnings at $2.64 EPS and FY2028 earnings […]
More Stories
Valuence Merger Corp. I (VMCA) & Its Rivals Financial Review
Volatility and Risk Valuence Merger Corp. I has a beta of 0.01, indicating that its stock price is 99% less...
Russia Will Help China Advance Submarine Technology, US Indo-Pacific Commander Says
By Frank Fang In return for China’s support during its war on Ukraine, Russia will likely assist Beijing to advance...
Financial Contrast: Carnival Co. & (NYSE:CUK) versus Viking (NYSE:VIK)
Viking (NYSE:VIK – Get Free Report) and Carnival Co. & (NYSE:CUK – Get Free Report) are both transportation companies, but...
Centaurus Financial Inc. Lowers Stock Holdings in iShares Core S&P Mid-Cap ETF (NYSEARCA:IJH)
Centaurus Financial Inc. cut its stake in shares of iShares Core S&P Mid-Cap ETF (NYSEARCA:IJH – Free Report) by 2.5%...
PepsiCo, Inc. (NASDAQ:PEP) Shares Purchased by Summit Trail Advisors LLC
Summit Trail Advisors LLC increased its position in shares of PepsiCo, Inc. (NASDAQ:PEP – Free Report) by 18.3% during the...
Costco Wholesale Co. (NASDAQ:COST) Shares Acquired by Daiwa Securities Group Inc.
Daiwa Securities Group Inc. boosted its stake in Costco Wholesale Co. (NASDAQ:COST – Free Report) by 19.0% in the third...